| Outcome Measures: |
Primary: The maximum plasma concentration (Cmax) of SP2086, Cmax (a measure of the body's exposure to SP2086) will be compared before and after administration of multiple doses of SP2086, up to Day 31|The maximum plasma concentration (Cmax) of SP2086 acid, Cmax (a measure of the body's exposure to SP2086 acid) will be compared before and after administration of multiple doses of SP2086, up to Day 31|The maximum plasma concentration (Cmax) of valsartan, Cmax (a measure of the body's exposure to valsartan) will be compared before and after administration of multiple doses of valsartan, up to Day 31|The area under the plasma concentration-time curve (AUC) of SP2086, AUC (a measure of the body's exposure to SP2086) will be compared before and after administration of multiple doses of SP2086, up to Day 31|The area under the plasma concentration-time curve (AUC) of SP2086 acid, AUC (a measure of the body's exposure to SP2086 acid) will be compared before and after administration of multiple doses of SP2086, up to Day 31|The area under the plasma concentration-time curve (AUC) of valsartan, AUC (a measure of the body's exposure to valsartan) will be compared before and after administration of multiple doses of valsartan, up to Day 31 | Secondary: The number of volunteers with adverse events as a measure of safety and tolerability, up to Day 31
|
